155 related articles for article (PubMed ID: 26659413)
1. A surprising case of inclusion body myositis with positive endomysial C5b-9 staining.
Buchman S; Bandyopadhyay S; Baccon J; Wicklund M
Muscle Nerve; 2016 Jun; 53(6):991-2. PubMed ID: 26659413
[No Abstract] [Full Text] [Related]
2. Coexistence of TDP-43 and C5b-9 staining of muscle in a patient with inclusion body myositis.
Law C; Li H; Bandyopadhyay S
BMJ Case Rep; 2021 Feb; 14(2):. PubMed ID: 33563691
[TBL] [Abstract][Full Text] [Related]
3. TDP-43 plasma levels do not differentiate sporadic inclusion body myositis from other inflammatory myopathies.
Kuiperij HB; Abdo WF; van Engelen BG; Schelhaas HJ; Verbeek MM
Acta Neuropathol; 2010 Dec; 120(6):825-6. PubMed ID: 21046407
[No Abstract] [Full Text] [Related]
4. Preservation of in vitro muscle fiber function in dermatomyositis and inclusion body myositis: a single fiber study.
Krivickas LS; Amato AA; Krishnan G; Murray AV; Frontera WR
Neuromuscul Disord; 2005 May; 15(5):349-54. PubMed ID: 15833427
[TBL] [Abstract][Full Text] [Related]
5. Cultured inclusion-body myositis muscle fibers do not accumulate beta-amyloid precursor protein and can be innervated.
McFerrin J; Engel WK; Askanas V
Neurology; 1999 Dec; 53(9):2184-7. PubMed ID: 10599804
[TBL] [Abstract][Full Text] [Related]
6. [Inclusion body myositis: clinical and myopathological features].
Xie H; Wang L; Shen D
Zhonghua Nei Ke Za Zhi; 1997 Sep; 36(9):610-2. PubMed ID: 10436972
[TBL] [Abstract][Full Text] [Related]
7. C5b-9 deposits on endomysial capillaries in non-dermatomyositis cases.
Braczynski AK; Harter PN; Zeiner PS; Drott U; Tews DS; Preusse C; Penski C; Dunst M; Weis J; Stenzel W; Mittelbronn M
Neuromuscul Disord; 2016; 26(4-5):283-91. PubMed ID: 27020463
[TBL] [Abstract][Full Text] [Related]
8. Sporadic inclusion body myositis misdiagnosed as idiopathic granulomatous myositis.
Lavian M; Goyal N; Mozaffar T
Neuromuscul Disord; 2016 Nov; 26(11):741-743. PubMed ID: 27692540
[TBL] [Abstract][Full Text] [Related]
9. C4d staining as immunohistochemical marker in inflammatory myopathies.
Pytel P
Appl Immunohistochem Mol Morphol; 2014 Oct; 22(9):696-704. PubMed ID: 24897075
[TBL] [Abstract][Full Text] [Related]
10. [Cytoplasmic body myopathy (spheroid body myopathy)].
Hara H; Wakayama Y
Ryoikibetsu Shokogun Shirizu; 2001; (35):439-42. PubMed ID: 11555982
[No Abstract] [Full Text] [Related]
11. Inclusion body myositis with human immunodeficiency virus infection: four cases with clonal expansion of viral-specific T cells.
Dalakas MC; Rakocevic G; Shatunov A; Goldfarb L; Raju R; Salajegheh M
Ann Neurol; 2007 May; 61(5):466-75. PubMed ID: 17366634
[TBL] [Abstract][Full Text] [Related]
12. Neuromuscular pathology case.
Lacomis D
J Clin Neuromuscul Dis; 2008 Dec; 10(2):79-82. PubMed ID: 19169096
[No Abstract] [Full Text] [Related]
13. Polymyositis: an overdiagnosed entity.
Hengstman GJ; van Engelen BG
Neurology; 2004 Jul; 63(2):402-3; author reply 403. PubMed ID: 15282847
[No Abstract] [Full Text] [Related]
14. Congenital myopathy with tubular aggregates and tubulofilamentous IBM-type inclusions.
Fidziańska A; Kamińska A; Ryniewicz B
Neuropediatrics; 2005 Feb; 36(1):35-9. PubMed ID: 15776320
[TBL] [Abstract][Full Text] [Related]
15. Tubuloreticular inclusions in inclusion body myositis.
Katzberg HD; Munoz DG
Clin Neuropathol; 2010; 29(4):262-6. PubMed ID: 20569678
[TBL] [Abstract][Full Text] [Related]
16. [Proximally accentuated increasing muscle weakness and myalgia. Inclusion body myositis].
Mosimann T
Praxis (Bern 1994); 2002 Oct; 91(44):1869-71. PubMed ID: 12442647
[No Abstract] [Full Text] [Related]
17. Cytosolic 5'-nucleotidase 1A autoantibody profile and clinical characteristics in inclusion body myositis.
Lilleker JB; Rietveld A; Pye SR; Mariampillai K; Benveniste O; Peeters MT; Miller JA; Hanna MG; Machado PM; Parton MJ; Gheorghe KR; Badrising UA; Lundberg IE; Sacconi S; Herbert MK; McHugh NJ; Lecky BR; Brierley C; Hilton-Jones D; Lamb JA; Roberts ME; Cooper RG; Saris CG; Pruijn GJ; Chinoy H; van Engelen BG;
Ann Rheum Dis; 2017 May; 76(5):862-868. PubMed ID: 28122761
[TBL] [Abstract][Full Text] [Related]
18. Pathogenesis of inclusion body myositis.
Greenberg SA
Curr Opin Rheumatol; 2020 Nov; 32(6):542-547. PubMed ID: 32941249
[TBL] [Abstract][Full Text] [Related]
19. Inflammatory myopathies: evaluation and management.
Greenberg SA
Semin Neurol; 2008 Apr; 28(2):241-9. PubMed ID: 18351525
[TBL] [Abstract][Full Text] [Related]
20. Understanding the immunopathogenesis of inclusion-body myositis: present and future prospects.
Dalakas MC
Rev Neurol (Paris); 2002 Oct; 158(10 Pt 1):948-58. PubMed ID: 12407303
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
